Pulmonary Function Testing (PFT) is a critical tool in diagnosing and managing patients with respiratory diseases. However, its interpretation can be complex and requires a comprehensive understanding of respiratory physiology. This article aims to provide a comprehensive guide to the interpretation of PFT.
Parameters such as Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and FEV1/FVC ratio are fundamental in PFT interpretation. FVC reflects the maximum volume of air that can be forcibly exhaled, while FEV1 measures the volume exhaled during the first second. The FEV1/FVC ratio is essential in differentiating between obstructive and restrictive lung diseases.
Spirometry is a key component of PFT. A reduced FEV1/FVC ratio (<70%) indicates obstructive lung disease. If this ratio is normal or high, but FVC and FEV1 are reduced, a restrictive pattern is suggested. The severity of the disease can be assessed by the degree of reduction in FEV1.
Measurement of lung volumes can help confirm restrictive diseases when spirometry is inconclusive. A reduced Total Lung Capacity (TLC) indicates restrictive lung disease. The Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) assesses the gas exchange capacity of the lung. A decreased DLCO may suggest interstitial lung disease or pulmonary vascular disease.
Interpretation of PFT should always be integrated with clinical context. Serial PFTs can be used to monitor disease progression or response to treatment. It is also essential in preoperative evaluation and disability assessment.
Interpreting PFT is a multifaceted process that requires a solid understanding of respiratory physiology and clinical correlation. Understanding the basic principles of PFT interpretation can significantly enhance clinical decision-making in patients with respiratory diseases.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation